No way [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2019-01-27 18:18 (762 d 01:17 ago) – Posting: # 19813
Views: 1,663

Dear yuvaneshwari,

» Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

» In the above scenario, can we consider for BCS based waiver approach ?

I think you have answered your own question. If solubility is the limiting factor, and your product has an improved solubility compared to the reference, how could you justify any kind of biowaiver ?

In any case: BCS-based biowaivers are only possible for class I and III products. Not the slightest chance if you're dealing with class II or IV.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,357 posts in 4,459 threads, 1,492 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Saturday 19:35 CET (Europe/Vienna)

The way to do research is to attack the facts
at the point of greatest astonishment.    Celia Green

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5